The therapeutical strategies for HER2-overexpressing breast cancer are: HER2-targeting antibodies (trastuzumab, pertuzumab) and HER2-directed antibody–drug conjugate (trastuzumab emtansine: T-DM1) [47]. Here, ERBB2 is linked to breast carcinoma.